Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Furosemide + niacin** is a combination of two distinct drugs: **furosemide**, a loop diuretic, and **niacin** (nicotinic acid, vitamin B3), a lipid-modifying agent. - **Furosemide** increases urine output by inhibiting sodium and chloride reabsorption in the kidneys, primarily used to manage edema associated with heart failure, liver disease, and kidney disease, as well as hypertension[1][4]. - **Niacin** is a form of vitamin B3 used to treat or prevent niacin deficiency and to manage hyperlipidemia by reducing hepatic synthesis and release of very-low-density lipoprotein (VLDL), leading to lower triglycerides and increased high-density lipoprotein (HDL) cholesterol[2][7]. There is no evidence that furosemide + niacin exists as a fixed-dose combination or unique pharmaceutical product; their combined use may occur in clinical practice when both indications overlap[1][2][5]. The combination may lead to enhanced diuretic and hypotensive effects[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on furosemide + niacin.